HR Execs on the Move

Berg Pharma

www.bergpharma.com

 
Berg Pharma focuses research on understanding how alterations in metabolism relate to disease onset. The company has a deep pipeline of early-stage technologies in CNS diseases and metabolic diseases that complement its late-stage clinical trial activity in cancer and prevention of chemotoxicity. Armed with use of the Berg Interrogative Biology™ discovery platform that translates biological output into therapeutic candidates, Berg Pharma is well positioned for rapid commercialization of its intellectual capital.
  • Number of Employees: 0-25
  • Annual Revenue: $1-10 Million
  • www.bergpharma.com
  • 500 Old Connecticut Path
    Framingham, MA USA 01701
  • Phone: 617.588.0083

Executives

Name Title Contact Details

Similar Companies

Global Napi Pharmaceuticals

Global Napi Pharmaceuticals is a Th October Egypt, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Stayma Consulting Services

Stayma Consulting Services is a Alpharetta, GA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Ambrilia Biopharma

Ambrilia Biopharma Inc. is a Verdun, QC-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

True Health

True Health (formerly Central Florida Family Health Center) is a non-profit patient-centered medical home that has been serving the Central Florida community since 1977. Our centers, conveniently located throughout Central Florida, aim to bring you ...

Accumulus

Accumulus Synergy is a global, non-profit organization that is developing a transformative data exchange platform that aims to enable enhanced collaboration and efficiency between life sciences organizations and global health authorities, while also affording users the ability to extract dynamic, data-driven insights from knowledge management. Sponsored by leading biopharmaceutical companies, Accumulus Synergy was formed in 2020 to create innovative solutions that can reduce regulatory review times and transform global data exchange. The non-profit company is creating a first-of-its-kind cloud-based platform between the biopharmaceutical industry and health authorities worldwide. The single-platform approach aims to improve speed, transparencies and efficiencies in the regulatory process by leveraging advanced technology and tools for data exchange. This will help reduce the cost of innovation and ultimately bring patients safe and effective medicines faster.